In patients with mild asthma, even a single day of repeated use of as-needed ICS–formoterol can protect against short term risk of a severe exacerbation as effectively as regular maintenance ICS, new research shows. While studies such as the 2018 SYGMA trials have already shown as-needed low-dose budesonide–formoterol reduces the long-term risk of severe exacerbations ...
More evidence to ban the blue puffer in favour of as-needed ICS-LABA
By Mardi Chapman
8 Oct 2020